Doctor Sophie Postel-Vinay
Dr Sophie Postel-Vinay, MD, PhD, is a clinician-scientist and medical oncologist specialising in early drug development, research team leader at Gustave Roussy (France), and affiliated professor at the University College London (UCL) Cancer Institute (UK).
She holds a PhD in cancer biology, awarded by the Institute of Cancer Research (London, UK) in 2012. Dr Postel-Vinay initially trained in medical oncology at Université Paris V and subsequently specialised in drug development at the Royal Marsden Hospital in London.
Appointed Assistant Professor at the Department of Therapeutic Innovation and Early Trials (DITEP) at Gustave Roussy in 2013, she secured a Clinician Scientist position in 2017, supported by an ATIP-Avenir grant from INSERM. In 2023, she was awarded an ERC Starting Grant, further consolidating her position as a scientific leader. From 2020 to 2022, she chaired the DITEP committee and currently provides scientific leadership across multiple early-phase clinical trials. Her work is strongly rooted in early-phase trial methodology, as well as preclinical and translational research.
Since 2023, she has led the institutionally accredited SIRIC (Integrated Cancer Research Site) programme at Gustave Roussy. In parallel, she joined the UCL Cancer Institute in November 2023, aiming to strengthen academic collaboration around innovative therapeutic strategies targeting rare sarcomas, in particular fusion-driven sarcomas affecting children, adolescents, and young adults, within a trans-age framework.
Her research focuses on identifying and targeting genetic vulnerabilities in cancer, at the crossroads of DNA repair, epigenetic regulation, and anti-tumour immunity.
Dr Postel-Vinay is an active member of several international learned societies (ESMO, AACR, ASCO, EACR), and serves on the Scientific Board of the European Association for Cancer Research. She contributes regularly to the organisation and scientific steering of internationally recognised conferences. Her scientific contributions have been acknowledged through several prestigious awards, including the Irène Joliot-Curie Prize from the French Academy of Sciences (2019), the Gallet and Breton Prize from the French National Academy of Medicine (2019), and the Raymond Rosen Prize from the French Foundation for Medical Research (2023).
Deeply committed to a translational and patient-centred approach, she strives to advance cancer treatment through innovative research that bridges clinical and scientific expertise.
